Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, March 31, 2016

Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review



open access
  
Conclusions
In conclusion, options to reduce the high BC incidence and mortality risk include PBSO and PM (BPM and CPM). The summary risk reduction estimates presented in our meta-analysis confirm that BRCA1/2 mutation carriers who have been treated with prophylactic surgery have a substantially reduced risk of BC and mortality. This meta-analysis and systematic review could serve as a helpful guide for clinicians during the discussion with their patients before the final prophylactic surgical decision is made. However, further prospective studies with larger sample size and longer follow-up periods are still required to get a more precise estimation of the benefits and potential harms of prophylactic surgeries among BRCA1 or BRCA2
mutation carriers.

TAKE-HOME MESSAGE

  • This was meta-analysis of 15 studies looked at clinical outcomes related to prophylactic mastectomy (PM) and bilateral salpingo-oophorectomy (PBSO) in women with BRCA1 and BRCA2 mutations. Bilateral PM significantly decreased breast cancer risk in both BRCA1 and BRCA2 mutation carriers (RR, 0.55 and 0.11, respectively), as did contralateral PM (RR, 0.072). PBSO and contralateral PM also reduced all-cause mortality in BRCA1/2 mutation carriers (HR, 0.35 and 0.51, respectively), while bilateral PM did not.
  • The analysis found that prophylactic surgeries reduce incidence and mortality related to breast cancer.

0 comments :

Post a Comment

Your comments?